Hands down, MILabs provides the most versatile one-stop solution for translational in vivo imaging. No matter what tracer, animal model, or modality – PET, SPECT, bioluminescence, fluorescence or X-ray CT – you’ll get images with the required visual acuity for bench-to-clinic translation without information loss Read more
Recent developments and improvements of multimodal imaging methods in animal research have substantially strengthened the options of in vivo tumor detection. Lütje et al. characterized four novel anti-PSMA drug conjugates labeled with 111In using high-resolution SPECT/CT. Read more
Optical colonoscopy remains the gold-standard method for early detection of colocrectal cancer. Carpenet et al. demonstrated that a 99mTc-labeled IgA antibody against the carcinoembryonic antigen is a promising tracer for diagnosis of colorectal cancer and distant metastases in the lung. Read more
To ensure availability of sufficient amounts of 99Mo for diagnostic imaging, the US Government announced plans for a new production facility in Janesville (WI). With the recent development of MILabs’ super-resolution G-SPECT* for large animal and human imaging, reduction of 99Mo may be possible. Read more
* G-SPECT is not available for clinical use, yet. Sale for such use depends on local (pre)market approval, including FDA and CE certifications.
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.